First, differences in histological heterogeneity in type II ovarian carcinoma, including high-grade serous, high-grade endometriod, and carcinosarcoma used to assess amplification KRAS/MAPK1 may produce significant variability among results. The gene discussed is KRAS; the disease is ovarian carcinoma.